In this edition:
Sotorasib vs. docetaxel in previously-treated KRASG1C2-mutated NSCLC
Atezolizumab in NSCLC ineligible for platinum-based chemo
Nivolumab + ipilimumab vs. continuation until progression in stage IV NSCLC
Pembrolizumab + pemetrexed & platinum in nonsquamous NSCLC
Pembrolizumab + chemo in squamous NSCLC
T-DXd in HER2-mutated NSCLC
Osimertinib in resected EGFR-mutated NSCLC
Sintilimab ± IBI305 + chemo in EGFR-mutated non-squamous NSCLC after progression on EGFR TKIs therapy
Tepotinib + osimertinib for EGFR-mutated NSCLC with MET amplification following progression with osimertinib
Associations between air pollution and NSCLC risk
Canakinumab in completely resected NSCLC
Community-based mass screening for lung cancer detection
Please login below to download this issue (PDF)